Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,865
archived clinical trials in
Multiple Sclerosis

T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated:  2/21/2016
Baylor Institute of Immunology Research - Clinical Rheumatology
mi
from
Dallas, TX
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated: 2/21/2016
Baylor Institute of Immunology Research - Clinical Rheumatology
mi
from
Dallas, TX
Click here to add this to my saved trials
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated:  2/21/2016
Emory University
mi
from
Atlanta, GA
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated: 2/21/2016
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Evaluating Intervention Responsiveness in People With Multiple Sclerosis
Evaluating Intervention Responsiveness in People With Multiple Sclerosis
Status: Enrolling
Updated:  2/22/2016
Motion Analysis Lab
mi
from
Baltimore, MD
Evaluating Intervention Responsiveness in People With Multiple Sclerosis
Evaluating Intervention Responsiveness in People With Multiple Sclerosis
Status: Enrolling
Updated: 2/22/2016
Motion Analysis Lab
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Cullman, AL
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Cullman, AL
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Fort Collins, CO
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Maitland, FL
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Maitland, FL
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
St. Petersburg, FL
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Grand Rapids, MI
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Traverse City, MI
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Traverse City, MI
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Dayton, OH
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Round Rock, TN
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Round Rock, TN
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Burlington, VT
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Burlington, VT
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Ft. Wayne, IN
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Ft. Wayne, IN
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Shreveport, LA
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
St Louis, MO
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Albuquerque, NM
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
New York, NY
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Charlotte, NC
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Seattle, WA
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Investigational Site Number 1405
mi
from
Geelong,
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Investigational Site Number 1405
mi
from
Geelong,
Click here to add this to my saved trials
Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS
Status: Enrolling
Updated:  2/26/2016
Partners MS Center, 1 Brookline Place Suite 225
mi
from
Brookline, MA
Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS
Status: Enrolling
Updated: 2/26/2016
Partners MS Center, 1 Brookline Place Suite 225
mi
from
Brookline, MA
Click here to add this to my saved trials
A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery
A Multi-Center Longitudinal Biorepository Study to Provide Biospecimens & Clinical Data From Neurological Disease Patients To Approved Pre-Clinical And Clinical Investigators for Drug & Biomarker Studies
Status: Enrolling
Updated:  3/1/2016
Sanguine Biosciences
mi
from
Los Angeles, CA
A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery
A Multi-Center Longitudinal Biorepository Study to Provide Biospecimens & Clinical Data From Neurological Disease Patients To Approved Pre-Clinical And Clinical Investigators for Drug & Biomarker Studies
Status: Enrolling
Updated: 3/1/2016
Sanguine Biosciences
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
Status: Enrolling
Updated:  3/9/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
Status: Enrolling
Updated: 3/9/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients
A Single-center Prospective Measurement of Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients.
Status: Enrolling
Updated:  3/17/2016
USF Carol and Frank Morsani Center for Advanced Healthcare
mi
from
Tampa, FL
Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients
A Single-center Prospective Measurement of Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients.
Status: Enrolling
Updated: 3/17/2016
USF Carol and Frank Morsani Center for Advanced Healthcare
mi
from
Tampa, FL
Click here to add this to my saved trials
Assistive Device Training in Multiple Sclerosis
Assistive Device Training for Functional Mobility and Connectivity in Multiple Sclerosis
Status: Enrolling
Updated:  3/17/2016
VA Portland Health Care System
mi
from
Portland, OR
Assistive Device Training in Multiple Sclerosis
Assistive Device Training for Functional Mobility and Connectivity in Multiple Sclerosis
Status: Enrolling
Updated: 3/17/2016
VA Portland Health Care System
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone
Relative Efficacy of Repeat Course of Intravenous methyLprednisolone and Intramuscular ACTH in the Treatment of Acute Relapse of Multiple Sclerosis After Sub Response to Initial Course of Intravenous Methylprednisolone (RECLAIM): a Single Center Pilot Study
Status: Enrolling
Updated:  3/21/2016
Neurologique Foundation, Inc.
mi
from
Ponte Vedra, FL
Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone
Relative Efficacy of Repeat Course of Intravenous methyLprednisolone and Intramuscular ACTH in the Treatment of Acute Relapse of Multiple Sclerosis After Sub Response to Initial Course of Intravenous Methylprednisolone (RECLAIM): a Single Center Pilot Study
Status: Enrolling
Updated: 3/21/2016
Neurologique Foundation, Inc.
mi
from
Ponte Vedra, FL
Click here to add this to my saved trials
Characterizing Upper Extremity Function in Individuals With Multiple Sclerosis
Characterizing Upper Extremity Function in Individuals With Multiple Sclerosis
Status: Enrolling
Updated:  3/22/2016
Mandell Center for Multiple Sclerosis at Mount Sinai Rehabilitation Hospital
mi
from
Hartford, CT
Characterizing Upper Extremity Function in Individuals With Multiple Sclerosis
Characterizing Upper Extremity Function in Individuals With Multiple Sclerosis
Status: Enrolling
Updated: 3/22/2016
Mandell Center for Multiple Sclerosis at Mount Sinai Rehabilitation Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Developing and Testing a Comprehensive MS Spasticity Management Program
Developing and Testing a Comprehensive MS Spasticity Management Program
Status: Enrolling
Updated:  3/25/2016
VA Portland Health Care System, Portland, OR
mi
from
Portland, OR
Developing and Testing a Comprehensive MS Spasticity Management Program
Developing and Testing a Comprehensive MS Spasticity Management Program
Status: Enrolling
Updated: 3/25/2016
VA Portland Health Care System, Portland, OR
mi
from
Portland, OR
Click here to add this to my saved trials
Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series
Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series
Status: Enrolling
Updated:  3/28/2016
Oakland University
mi
from
Rochester, MI
Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series
Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series
Status: Enrolling
Updated: 3/28/2016
Oakland University
mi
from
Rochester, MI
Click here to add this to my saved trials
A Pilot Study of Lithium in Progressive Multiple Sclerosis
A Pilot Trial of Lithium in Progressive Multiple Sclerosis
Status: Enrolling
Updated:  3/30/2016
Kirklin Clinic
mi
from
Birmingham, AL
A Pilot Study of Lithium in Progressive Multiple Sclerosis
A Pilot Trial of Lithium in Progressive Multiple Sclerosis
Status: Enrolling
Updated: 3/30/2016
Kirklin Clinic
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Pilot Study of Lithium in Progressive Multiple Sclerosis
A Pilot Trial of Lithium in Progressive Multiple Sclerosis
Status: Enrolling
Updated:  3/30/2016
Birmingham VA Medical Center, Birmingham, AL
mi
from
Birmingham, AL
A Pilot Study of Lithium in Progressive Multiple Sclerosis
A Pilot Trial of Lithium in Progressive Multiple Sclerosis
Status: Enrolling
Updated: 3/30/2016
Birmingham VA Medical Center, Birmingham, AL
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/30/2016
Albany Advanced Imaging
mi
from
Albany, NY
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/30/2016
Albany Advanced Imaging
mi
from
Albany, NY
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/30/2016
Fallon Wellness Pharmacy
mi
from
Latham, NY
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/30/2016
Fallon Wellness Pharmacy
mi
from
Latham, NY
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/30/2016
Northeast Eye Center
mi
from
Latham, NY
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/30/2016
Northeast Eye Center
mi
from
Latham, NY
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/30/2016
The MS Center of Northeastern New York
mi
from
Latham, NY
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/30/2016
The MS Center of Northeastern New York
mi
from
Latham, NY
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/30/2016
Cleveland Clinic
mi
from
Cleveland, OH
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/30/2016
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/30/2016
Retina Vitreous Center
mi
from
Edmond, OK
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/30/2016
Retina Vitreous Center
mi
from
Edmond, OK
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/30/2016
Lynn Health Science Institute
mi
from
Oklahoma City, OK
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/30/2016
Lynn Health Science Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/30/2016
Radiology Associates (X-ray facility only)
mi
from
Oklahoma City, OK
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/30/2016
Radiology Associates (X-ray facility only)
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/30/2016
Pfizer Investigational Site
mi
from
Cleveland, OH
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/30/2016
Pfizer Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/30/2016
Pfizer Investigational Site
mi
from
Edmond, OK
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/30/2016
Pfizer Investigational Site
mi
from
Edmond, OK
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/30/2016
Pfizer Investigational Site
mi
from
Oklahoma City, OK
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/30/2016
Pfizer Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Effects of Dalfampridine on Cognition in Multiple Sclerosis
Effects of Dalfampridine on Cognition in Multiple Sclerosis
Status: Enrolling
Updated:  4/12/2016
Buffalo General Hospital
mi
from
Buffalo, NY
Effects of Dalfampridine on Cognition in Multiple Sclerosis
Effects of Dalfampridine on Cognition in Multiple Sclerosis
Status: Enrolling
Updated: 4/12/2016
Buffalo General Hospital
mi
from
Buffalo, NY
Click here to add this to my saved trials
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Status: Enrolling
Updated:  4/14/2016
North Central Neurology Assoc PC
mi
from
Cullman, AL
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Status: Enrolling
Updated: 4/14/2016
North Central Neurology Assoc PC
mi
from
Cullman, AL
Click here to add this to my saved trials
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Status: Enrolling
Updated:  4/14/2016
Phoenix Neurological Associates
mi
from
Phoenix, AZ
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Status: Enrolling
Updated: 4/14/2016
Phoenix Neurological Associates
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Status: Enrolling
Updated:  4/14/2016
Stanford Univ Med Ctr
mi
from
Stanford, CA
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Status: Enrolling
Updated: 4/14/2016
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Status: Enrolling
Updated:  4/14/2016
IMMUNOe International Research Center
mi
from
Centennial, CO
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Status: Enrolling
Updated: 4/14/2016
IMMUNOe International Research Center
mi
from
Centennial, CO
Click here to add this to my saved trials
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Status: Enrolling
Updated:  4/14/2016
Michigan Institute for Neurological Disorders
mi
from
Farmington Hills, MI
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Status: Enrolling
Updated: 4/14/2016
Michigan Institute for Neurological Disorders
mi
from
Farmington Hills, MI
Click here to add this to my saved trials